Enlitic has locked in binding commitments for a conditional A$15 million capital raise alongside a convertible note conversion, setting the stage for a clearer path to cashflow break-even and accelerated rollout of its SaaS platform.
- A$15 million conditional placement at A$0.004 per CDI
- Convertible notes worth A$10 million to convert into equity
- Proposed 10:1 share consolidation post transactions
- Funds aimed at scaling SaaS sales and marketing
- Pro forma cash of ~A$18 million to support operations
Capital Raise and Debt Conversion Simplify Enlitic's Balance Sheet
Enlitic (ASX:ENL) has secured binding commitments for a conditional placement to raise approximately A$15 million at a steep 20% discount to its last traded price, priced at A$0.004 per new CHESS Depositary Interest (CDI). This capital injection is paired with a proposed conversion of existing secured convertible notes worth A$10 million into equity, effectively extinguishing debt and simplifying the company’s capital structure.
The combined effect of the placement and note conversion will see Enlitic’s issued shares balloon from roughly 833 million to over 7 billion on a pre-consolidation basis, prompting a planned 10:1 share consolidation to tidy up the capital structure. This consolidation is expected to take effect after shareholder approvals and completion of the capital raising.
Funding SaaS Growth and Operational Break-Even
The proceeds from the capital raise are earmarked primarily for accelerating the commercialisation and sales expansion of Enlitic’s SaaS-based Ensight platform, which is gaining traction in large enterprise healthcare settings globally. The funds will also support ongoing research and development, regulatory compliance, customer service scaling, and general corporate overheads.
With a cash balance of approximately A$2.9 million as of 30 June 2026, the conditional placement and note conversion are expected to boost pro forma cash reserves to about A$18 million, providing a runway of over 12 months. Enlitic anticipates this funding will sustain operations through to cashflow break-even, a milestone that would mark a significant inflection point for the company’s financial health.
Commercial Momentum Underpins Confidence
Enlitic’s CEO Michael Sistenich emphasised the pivotal nature of this capital raising, highlighting the company’s strengthened balance sheet and debt-free position as key enablers for scaling sales efforts. The company has been steadily building commercial momentum, with a growing pipeline of customers and signed contracts, including marquee US healthcare institutions.
The Ensight platform, which standardises and governs medical imaging data to enable AI-driven workflow automation, is central to Enlitic’s growth strategy. The company has secured eight OEM agreements and operates across 15 countries, with nearly 1,000 clinical sites onboarded. These integrations reduce deployment complexity and accelerate revenue conversion, shortening sales cycles from up to two years to an expected six months.
Shareholder Approvals and Risks Ahead
The capital raise and note conversion are conditional on shareholder approval at an extraordinary general meeting expected in late July or early August 2026, as well as necessary ASX waivers. The offer is not underwritten, introducing execution risk. If approvals are not secured, Enlitic faces going concern risks and potential insolvency issues.
Investors should also consider dilution risks, with the number of shares on issue potentially increasing by up to 750% post transactions, excluding any additional shares issued under the planned security purchase plan targeting up to A$1 million. The company has disclosed a comprehensive list of risks including market competition, AI technology challenges, integration complexities, and regulatory uncertainties.
What’s Next for Enlitic
Following the capital raise, Enlitic aims to accelerate the rollout of Ensight’s next-generation versions and secure recurring SaaS contracts through its expanding OEM channels. The company is targeting a transition from one-off migration revenues to a high-margin, subscription-based revenue model that should drive sustainable growth.
With a cleaner balance sheet and a stronger cash position, Enlitic is poised to deepen its penetration in the large and growing medical imaging market. However, the company’s ability to execute on these ambitions hinges on shareholder support and successful integration of its SaaS platform into complex healthcare environments.
Bottom Line?
Enlitic’s capital raise and debt conversion clear financial hurdles, but shareholder approval and execution risks remain critical to watch.
Questions in the middle?
- Will Enlitic secure shareholder approval for its conditional placement and note conversion?
- How quickly can Enlitic convert its growing pipeline into recurring SaaS revenue?
- Can the company sustain operational momentum post share consolidation and capital restructure?